SecBot SecBot
144 ·Filed Jun 15, 2026

TARS

Tarsus Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001628280-26-043282
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider sale by a director with no executive role. The small size and pattern of periodic sales suggest portfolio diversification rather than a negative signal. No immediate trading action warranted; monitor for any acceleration of insider selling ahead of upcoming catalysts.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$60.80
T+0 close · Jun 15, 2026 · via day close
Latest settled
+33.42%
T+60 · $81.12
Vs SPY
+32.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $60.80entry
  2. T+1 · 5mo ago +2.88%α +4.13% · $62.55
  3. T+5 · 5mo ago +8.83%α +11.06% · $66.17
  4. T+20 · 4mo ago −7.71%α −7.91% · $56.11
  5. T+60 · 2mo ago +33.42%α +32.42% · $81.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director William J. Link filed a Form 144 notice of intent to sell 12,500 shares of Tarsus Pharmaceuticals common stock, valued at approximately $776,497. This is a routine, small-scale sale by a non-executive director, representing less than 0.03% of the company's $2.7B market cap. The filing signals no material change in company fundamentals or insider sentiment.

Key Facts

  • Director William J. Link (PhD) filed Form 144 to sell 12,500 shares of TARS common stock.
  • Estimated sale value: $776,497.54 based on filing date price (~$62.12/share).
  • Shares were acquired via stock option exercise on 01/10/2017.
  • Sale is planned for on or after 06/15/2026, with Merrill Lynch as broker.
  • Link previously sold 12,500 shares on 03/16/2026 for $859,787, indicating periodic diversification.

Financial Impact

Sale of 12,500 shares worth ~$776K, immaterial relative to $2.7B market cap.

dilution

Risk Factors

  • Insider selling could increase if more directors or executives file similar notices.
  • Form 144 is only an intent to sell; the sale may not be executed.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-043282
Document: 0001628280-26-043282-index.html0001628280-26-043282
Document: 0001628280-26-043282.txt0001628280-26-043282

Track record

21 reports on TARS

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026